In PD, all major DMT trials—including those of coenzyme Q10, creatine, pramipexole, and pioglitazone—have failed to slow disease progression, and ongoing studies targeting α-synuclein, mitochondrial dysfunction, and neuroinflammation have yet to yield positive results [10]. This evidence concerns the gene SNCA and Parkinson disease.